CorMedix (NASDAQ: CRMD) reported Q4 EPS of $0.22, $0.05 better than the analyst estimate of $0.17. Revenue for the quarter came in at $31.2 million versus the consensus estimate of $31 million.

For earnings history and earnings-related data on CorMedix (CRMD) click here.